Newsroom
Sorted by: Latest
-
Kept Alive by ECMO Until Heart Transplant: Sahara Romero's Story of Survival and Recovery, with ECMOlife by Eurosets
MEDOLLA, Italy--(BUSINESS WIRE)--“Now, for the first time in years, I can live without constantly fearing something could go wrong.” That's how Sahara Romero told her story, presented at the EuroELSO Congress in Dublin (6-8 May), dedicated to lifesaving extracorporeal therapies. Hers is a remarkable journey back to life, where clinical expertise and advanced life-support technologies came together to radically change her fate. Sahara has lived with a serious heart condition since early adolesce...
-
Omdia: Social media advertising to command nearly half of global online ad revenue by 2030 as market reaches $640 billion
LONDON--(BUSINESS WIRE)--Social media advertising revenue is projected to rise at a compound annual growth rate (CAGR) of 12% over the next five years, reaching $640 billion by the end of 2030, according to Omdia’s Social Media Advertising Market Landscape 2026 report, its first-ever research focusing exclusively on social media advertising. During the same period, social media’s share of total online advertising is expected to increase by 10 percentage points, from 33% to 44%, making it one of...
-
Datang Mobile、KPN、NEC、WilusがSisvel POS特許プールに新たに加入 ― 早期参加インセンティブ締め切り間近
ルクセンブルク--(BUSINESS WIRE)--(ビジネスワイヤ) -- Datang Mobile、KPN、NEC、Wilusの4社が、SisvelのPOS(販売時点情報管理)特許プールに新たに加入しました。これにより、BlackBerry、Huawei、JVCKENWOOD、LG Electronics、Nokia、シズベル、SKテレコムを含む11社が本プログラムを通じて2G~5Gのセルラー関連特許ポートフォリオライセンスを提供することになります。 Sisvel POSのライセンサーが早期参加によるインセンティブの恩恵を受けられる期間は、5月15日に終了する予定です。加入を検討しているセルラー関連特許所有者の方々は、できるだけ早くシズベルにご連絡ください。 4月初旬に発表された、POS分野を対象とする業界初の本特許プールには、Huawei、LG Electronics、Nokia が創設ライセンサーとして名を連ねています。 「これまでに市場から大きな反響をいただいておりますが、この度、Datang、KPN、NEC、Wilusの各社を新たなライセンサーとして迎えることができ、大...
-
Omdia: Desktop Monitor Shipments Reach 133.4 Million Units in 2025 as Gaming Monitors Fuel Recovery
LONDON--(BUSINESS WIRE)--Desktop monitor shipments reached 133.4 million units in 2025, growing 4.3% year-on-year, signaling a recovery from post-pandemic disruptions. This expansion reflects the evolution of monitors into versatile, high-value tools for laptop-dominated environments, with gaming fueling interest in high-performance displays. Gaming monitor shipments are projected to expand to 43 million units in 2026, supported by increased cost-effectiveness and added functionality. This tren...
-
New Research From Infobip Finds Disconnected Data and Systems Prevent Brands From Automating Customer Journeys at Scale
VODNJAN, Croatia--(BUSINESS WIRE)--Infobip’s 2026 Customer Experience Maturity Report reveals gap between communications infrastructure investment and CX performance....
-
XTransfer Joins the Chile Fintech Forum 2026
SANTIAGO, Chile--(BUSINESS WIRE)--XTransfer, the world’s leading B2B cross-border trade payment platform, participated in the Chile Fintech Forum 2026 as Platinum sponsor and introduced X-Net in Latin America for the first time. X-Net is a globally unified B2B cross-border settlement network and risk management platform designed to connect banks and financial institutions with SMEs, supporting more efficient, secure, and inclusive cross-border payment solutions as China–Latin America trade cont...
-
Enterprise Therapeutics Achieves Primary Efficacy Outcome in Phase 2 Clinical Trial for Cystic Fibrosis With Novel Inhaled ENaC Blocker ETD001
BRIGHTON, England--(BUSINESS WIRE)--Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of people with respiratory diseases, today announced that its Phase 2 trial for ETD001, the Company’s lead candidate for treatment of cystic fibrosis (CF), achieved its primary efficacy outcome. The trial aimed to investigate the efficacy, safety, tolerability and pharmacokinetics of inhaled ETD001 in the 10%...
-
BETA Technologies, Inc. Announces First Quarter 2026 Results
SOUTH BURLINGTON, Vt.--(BUSINESS WIRE)--BETA Technologies, Inc. (NYSE: BETA) (“BETA” or the “Company”), an electric aerospace company, today announced its financial and operating results for the first quarter ended March 31, 2026. “Since the beginning of the year, BETA has made critical progress in support of our stepwise approach to electrify aviation, demonstrating our leadership position in the advanced air mobility sector as we prepare to enter eIPP operations,” said Kyle Clark, President a...
-
UGI International Commences Senior Notes Offering
VALLEY FORGE, Pa.--(BUSINESS WIRE)--UGI Corporation (“UGI” or the “Company”) (NYSE: UGI) announced today that its indirect, wholly owned subsidiary, UGI International, LLC (“UGI International”), intends to offer €300,000,000 in aggregate principal amount of senior notes (the “Notes”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the U.S. Securities Act of 1933, as amended (the “Securities Act”), and to non-U.S. persons outside the United States...
-
再生医療における画期的なBEES-HAUS細胞療法(パラクリン効果と細胞の定着による尿道狭窄症治療)を簡略化したBHES-HAUSの臨床結果をAUA 2026で発表
東京--(BUSINESS WIRE)--(ビジネスワイヤ) -- BEES-HAUS細胞療法による尿道狭窄の創傷治癒メカニズムを解明した画期的な科学的発見が、インド、日本両国の医師・科学者チームにより報告されました。臨床的な安全性と有効性を示すものであり、再生医療におけるこのような発見は初めてとなります。 この研究では、尿道狭窄の治療に2次元(2D)培養された自己口腔粘膜上皮細胞群と、フェスティゲル(Festigel)スキャフォールドで3次元(3D)培養された同細胞群 を混合するハイブリッドアプローチが採用されました。2次元培養細胞が産生するIGF-1のパラクリン効果と、3次元培養細胞の切開創への生着が相まって尿道上皮欠損を修復するというメカニズムが考察され、結果がFrontiers in Urology誌に発表されました。研究者らは、この成果は、in vitroの組織工学で培養された細胞が、in vivoでの治療で良好な臨床結果を出したという意味で世界初のものであり、尿道上皮の損傷の回復につながっていると指摘しています。また、患者にとっては狭窄の再発の可能性が少なく、生活の質を向...